NEW PRAGUE, Minn. / Nov 01, 2023 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16, 2023 at the Westin NY Grand Central in New York City.
Electromed’s management team will engage in investor 1x1s on Thursday, November 16, 2023.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
| Last Trade: | US$24.10 |
| Daily Change: | -1.17 -4.63 |
| Daily Volume: | 44,793 |
| Market Cap: | US$201.960M |
August 26, 2025 April 03, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
